Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC

(RARE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Ultragenyx Pharmaceutical : to Host Conference Call for Fourth Quarter and Full-Year 2018 Financial Results and Corporate Update

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 08:45am EST

NOVATO, Calif., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Tuesday, February 19, 2019 at 5pm ET to discuss its financial results and corporate update for the fourth quarter and the year ended December 31, 2018.

The live and replayed webcast of the call will be available through the company's website at http://ir.ultragenyx.com/events.cfm. To participate in the live call by phone, dial (855) 797-6910 (USA) or 262-912-6260 (International) and enter the passcode 6689186. The replay of the call will be available for one year.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are no approved therapies.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at www.ultragenyx.com.

Contact Ultragenyx Pharmaceutical Inc.
Investors & MediaDanielle Keatley
415-475-6876

Source: Ultragenyx Pharmaceutical Inc.

Disclaimer

Ultragenyx Pharmaceutical Inc. published this content on 12 February 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 12 February 2019 13:44:04 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ULTRAGENYX PHARMACEUTICAL
02/16Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita (bu..
AQ
02/15Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita fro..
AQ
02/14ULTRAGENYX PHARMACEUTICAL : and Kyowa Kirin Announce Positive 64-Week Results fo..
AQ
02/12ULTRAGENYX PHARMACEUTICAL : to Host Conference Call for Fourth Quarter and Full-..
PU
02/12ULTRAGENYX PHARMACEUTICAL : to Host Conference Call for Fourth Quarter and Full-..
AQ
02/04ULTRAGENYX PHARMACEUTICAL INC. : Change in Directors or Principal Officers (form..
AQ
02/04Ultragenyx Appoints Shehnaaz Suliman, M.D., to Board of Directors
GL
01/22ULTRAGENYX PHARMACEUTICAL : Announces Positive Topline Data from Ongoing Long-Te..
AQ
01/15ULTRAGENYX PHARMACEUTICAL INC. : Entry into a Material Definitive Agreement (for..
AQ
01/07ULTRAGENYX PHARMACEUTICAL INC. : Regulation FD Disclosure, Other Events, Financi..
AQ
More news
Financials ($)
Sales 2018 49,3 M
EBIT 2018 -376 M
Net income 2018 -201 M
Finance 2018 285 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 52,3x
EV / Sales 2019 26,2x
Capitalization 2 865 M
Chart ULTRAGENYX PHARMACEUTICAL INC
Duration : Period :
Ultragenyx Pharmaceutical Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 72,4 $
Spread / Average Target 28%
EPS Revisions
Managers
NameTitle
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Wladimir Hogenhuis Chief Operating Officer
Shalini Sharp Chief Financial Officer & Executive Vice President
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Sector and Competitors
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC30.29%2 865
GILEAD SCIENCES8.06%87 436
VERTEX PHARMACEUTICALS13.49%48 081
REGENERON PHARMACEUTICALS13.51%45 520
GENMAB-5.01%9 438
SAREPTA THERAPEUTICS INC26.87%9 252